Patents by Inventor David B. Karpf

David B. Karpf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
    Patent number: 10098843
    Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: October 16, 2018
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
  • COMPOSITIONS OF 5-ETHYL-2--PYRIMIDINE
    Publication number: 20160213618
    Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
    Type: Application
    Filed: January 21, 2016
    Publication date: July 28, 2016
    Inventors: Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
  • Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
    Patent number: 9241924
    Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: January 26, 2016
    Assignee: CYMABAY THERAPEUTICS, INC.
    Inventors: Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
  • Methods for avoiding edema in the treatment or prevention of PPAR?-responsive diseases, including cancer
    Patent number: 8288438
    Abstract: Compounds, compositions, and methods of avoiding edema while treating or preventing PPAR?-mediated diseases, including cancer, using derivatives and prodrugs are provided.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: October 16, 2012
    Assignees: Metabolex, Inc., Dia Tex, Inc.
    Inventors: Martin E. Sanders, David B. Karpf
  • COMPOSITIONS OF 5-ETHYL-2--PYRIMIDINE
    Publication number: 20110318418
    Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
    Type: Application
    Filed: June 21, 2011
    Publication date: December 29, 2011
    Inventors: Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
  • Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders
    Publication number: 20080194646
    Abstract: Compounds, compositions, and methods of treating or preventing PPAR?-mediated diseases, including cancer, using phenoxy acetic acid derivatives and prodrugs are provided.
    Type: Application
    Filed: March 21, 2006
    Publication date: August 14, 2008
    Inventors: Martin E. Sanders, David B. Karpf
  • Dual specificity tumor killing vectors driven by the telomerase promoter
    Publication number: 20030099616
    Abstract: It has been discovered that the specificity of multiple transcriptional regulatory elements can be combined to make vector systems that selectively target cancer cells. The promoter for telomerase reverse transcriptase (TERT) can be combined in a remarkably synergistic fashion with another promoter that has expression restricted to cancer cells or a particular tissue type. The two promoters work synergistically for exquisite targeting of the malignant cells—where it causes cell lysis while leaving neighboring healthy cells intact.
    Type: Application
    Filed: July 25, 2002
    Publication date: May 29, 2003
    Inventors: John M. Irving, David B. Karpf, J. Michael Schiff
  • METHOD OF LESSENING THE RISK OF VERTEBRAL FRACTURES
    Publication number: 20010051616
    Abstract: Alendronate, a bisphosphonate, when administered daily over a substantial period of time, can reduce the rate of vertebral fractures in post-menopausal women. Further it can reduce the number and severity of fractures. Also, administration of alendronate can prevent spinal deformity, and loss in height.
    Type: Application
    Filed: February 17, 1995
    Publication date: December 13, 2001
    Inventors: DAVID B. KARPF, THOMAS P. CAPIZZI, HUI QUAN, ARTHUR C. SANTORA, ASHLEY J. YATES
  • Prevention of tooth loss by the administration of alendronate or its salts
    Patent number: 5914099
    Abstract: Alendronate, a bisphosphonate can prevent tooth loss not necessarily associated with periodontal disease. Preferably, alendronate (or a pharmaceutically acceptable salt thereof) is given daily for an extended period of time.
    Type: Grant
    Filed: November 4, 1997
    Date of Patent: June 22, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Ashley John Yates, David B. Karpf
  • Method of lessening the risk of non-vertebral bone fractures
    Patent number: 5804570
    Abstract: Alendronate, a bisphosphonate, when administered daily over a substantial period of time, can reduce the rate of non-vertebral fractures, in post-menopausal women.
    Type: Grant
    Filed: June 3, 1997
    Date of Patent: September 8, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Arthur C. Santora, II, David B. Karpf, William J. Polvino, Deborah Ruth Shapiro, Desmond E. Thompson, Ashley John Yates